BR112017004048A2 - formulações de pó inalável de oligômeros de alginato - Google Patents

formulações de pó inalável de oligômeros de alginato

Info

Publication number
BR112017004048A2
BR112017004048A2 BR112017004048A BR112017004048A BR112017004048A2 BR 112017004048 A2 BR112017004048 A2 BR 112017004048A2 BR 112017004048 A BR112017004048 A BR 112017004048A BR 112017004048 A BR112017004048 A BR 112017004048A BR 112017004048 A2 BR112017004048 A2 BR 112017004048A2
Authority
BR
Brazil
Prior art keywords
particles
alginate oligomer
phospholipid
powder formulations
inhalable powder
Prior art date
Application number
BR112017004048A
Other languages
English (en)
Inventor
Bakle Anand
Dessen Arne
Nyambura Bildad
Original Assignee
Algipharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Algipharma As filed Critical Algipharma As
Publication of BR112017004048A2 publication Critical patent/BR112017004048A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734—Alginic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a invenção fornece partículas secas por pulverização para inalação, as referidas partículas consistindo em (i) pelo menos cerca de 70% p/p de um oligômero de alginato, (ii) pelo menos cerca de 10% p/p, no total, de um fosfolipídeo e um composto antiaderente, em que o referido fosfolipídeo é sólido à temperatura ambiente, e em que o referido fosfolipídeo está presente em não menos de 0,5% p/p e o referido composto antiaderente está presente em não menos de 0,5% p/p, e (iii) não mais do que cerca de 10% p/p de outros excipientes. a invenção fornece ainda um novo método para a preparação das referidas partículas, cápsulas e inaladores de pó seco compreendendo as referidas partículas e a utilização terapêutica das referidas partículas, em particular no tratamento ou prevenção de uma infecção respiratória ou um distúrbio respiratório.
BR112017004048A 2014-08-29 2015-08-28 formulações de pó inalável de oligômeros de alginato BR112017004048A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1415381.1A GB201415381D0 (en) 2014-08-29 2014-08-29 Inhalable powder formulations of alginate oligomers
PCT/EP2015/069785 WO2016030524A1 (en) 2014-08-29 2015-08-28 Inhalable powder formulations of alginate oligomers

Publications (1)

Publication Number Publication Date
BR112017004048A2 true BR112017004048A2 (pt) 2017-12-05

Family

ID=51752384

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017004048A BR112017004048A2 (pt) 2014-08-29 2015-08-28 formulações de pó inalável de oligômeros de alginato

Country Status (14)

Country Link
US (2) US20180235879A1 (pt)
EP (1) EP3185853B1 (pt)
JP (1) JP6707076B2 (pt)
KR (1) KR102582982B1 (pt)
CN (2) CN106659689B (pt)
AU (1) AU2015308381B2 (pt)
BR (1) BR112017004048A2 (pt)
CA (1) CA2959101A1 (pt)
DK (1) DK3185853T3 (pt)
ES (1) ES2972433T3 (pt)
FI (1) FI3185853T3 (pt)
GB (1) GB201415381D0 (pt)
RU (1) RU2708397C1 (pt)
WO (1) WO2016030524A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3219705T3 (da) 2005-12-28 2020-04-14 Vertex Pharma Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
ES2858351T3 (es) 2010-04-22 2021-09-30 Vertex Pharma Compuesto intermedio para proceso de producción de compuestos de cicloalquilcaraboxamido-indol
RU2744460C2 (ru) 2014-04-15 2021-03-09 Вертекс Фармасьютикалз Инкорпорейтед Фармацевтические композиции для лечения заболеваний, опосредованных муковисцидозным трансмембранным регулятором проводимости
US10568894B2 (en) 2016-06-03 2020-02-25 Otitopic Inc. Dry powder formulations for inhalation
EP3565848A4 (en) 2017-01-03 2020-09-02 The University of North Carolina at Chapel Hill NITROGEN OXIDE RELEASING ALGINATES AS BIODEGRADABLE ANTIBACTERIAL SCAFFOLDINGS AND ASSOCIATED PROCESSES
GB201702161D0 (en) * 2017-02-09 2017-03-29 Algipharma As A companion diagnostic method for use in the treatment of cystic fibrosis with alginate oligomers
EP3600338A4 (en) 2017-03-28 2020-10-28 The University of North Carolina at Chapel Hill NITRIC OXIDE RELEASING POLYAMINOGLYCOSIDES AS BIODEGRADABLE ANTIBACTERIAL SCAFFOLDS AND RELATED PROCESSES
JP7565588B2 (ja) 2018-03-06 2024-10-11 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 生分解性の抗菌性足場としての一酸化窒素放出性シクロデキストリンおよびそれに関する方法
JP7354132B2 (ja) * 2018-03-19 2023-10-02 アルギファルマ エーエス マイクロ粒子／ナノ粒子が粘液層を通って移動するのを強化するためのアルギネートオリゴマーの使用
EP3902841A4 (en) 2018-12-28 2022-09-28 The University of North Carolina at Chapel Hill NITRIC OXIDE RELEASING ANTIBACTERIAL POLYMERS AND SCAFFOLDS MADE THEREOF AND METHODS RELATED THEREOF
CN111202723A (zh) * 2020-02-15 2020-05-29 江苏艾立康药业股份有限公司 一种达芦那韦吸入干粉药物组合物及其制备方法
WO2021183371A1 (en) * 2020-03-11 2021-09-16 Purdue Research Foundation Nano-composite microparticles of polymyxin
CN113491678B (zh) * 2020-04-07 2023-01-20 知和(山东)大药厂有限公司 一种盐酸阿比朵尔吸入剂及其制备方法
WO2022029604A1 (en) 2020-08-07 2022-02-10 Council For Scientific And Industrial Research Microemulsion drug delivery system for treatment of acute respiratory distress syndrome
US20240252431A1 (en) * 2021-07-20 2024-08-01 Onconox Inc. Pulmonary biguanide formulations and delivery devices
WO2023028354A1 (en) * 2021-08-26 2023-03-02 Celestial Therapeutics, Inc Method for generating dry powder suitable for inhalation/intranasal/intratracheal administration of antimicrobial phospholipid compositions

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7221691A (en) 1990-01-23 1991-08-21 Terje Espevik Mannuronic acid containing alginate wound healing composition and method
US5169840A (en) 1991-03-27 1992-12-08 Nobipols Forskningsstiftelse Diequatorially bound β-1, 4 polyuronates and use of same for cytokine stimulation
NO305033B1 (no) 1997-05-09 1999-03-22 Algipharma As Fremgangsmate for fremstilling av uronsyreblokker fra alginat
EP1137402A1 (en) * 1998-12-08 2001-10-04 Phares Pharmaceutical Research N.V. Phospholipid compositions
EP1148905A2 (de) * 1999-02-03 2001-10-31 Max-Delbrück-Centrum Für Molekulare Medizin Druckluftinhalator zur pulmonalen applikation liposomalen pulver-aerosols sowie dafür geeignete pulver-aerosole
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
NO326145B1 (no) 2001-11-30 2008-10-06 Fmc Biopolymer As Fremgangsmate for a stimulere vektokning hos pattedyr, fugler og krypdyr.
KR20050011741A (ko) * 2002-04-11 2005-01-29 메드이뮨 백신즈 인코포레이티드 분무 건조에 의한 생물학적 활성 물질의 보존
US20120321717A1 (en) * 2003-04-14 2012-12-20 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
ES2656017T3 (es) 2004-06-24 2018-02-22 Vertex Pharmaceuticals Incorporated Moduladores de transportadores del casete de unión a ATP
GB0515492D0 (en) * 2005-07-28 2005-08-31 Reckitt Benckiser Healthcare Improvements in or relating to compositions,articles and methods
GB2430881B (en) * 2005-10-06 2010-10-13 Ntnu Technology Transfer As Oligoelectrolyte polyols for the treatment of mucosal hyperviscosity
EP1945632B1 (en) 2005-11-08 2013-09-18 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of atp-binding cassette transporters
ES2377840T3 (es) 2006-05-12 2012-04-02 Vertex Pharmaceuticals, Inc. Composiciones de N-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolina-3-carboxamida
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0707096D0 (en) 2007-04-12 2007-05-23 Ntnu Technology Transfer As Method
CA2699292A1 (en) 2007-09-14 2009-03-26 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
EP3012250B1 (en) 2007-11-16 2017-11-08 Vertex Pharmaceuticals Incorporated Isoquinoline modulators of atp-binding cassette transporters
RU2527894C2 (ru) * 2007-11-27 2014-09-10 Альгифарма ИПР АС Использование альгинатных олигомеров в борьбе с биопленками
JP2011506331A (ja) 2007-12-07 2011-03-03 バーテックス ファーマシューティカルズ インコーポレイテッド ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の処方物
EP3683218B1 (en) 2007-12-07 2024-09-18 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
US20100036130A1 (en) 2007-12-07 2010-02-11 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
NZ612635A (en) 2007-12-07 2015-06-26 Vertex Pharma Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
EP2243490B1 (en) * 2007-12-28 2012-06-13 Shanghai Institute of Pharmaceutical Industry Insulin nasal powder inhalation
ME03019B (me) 2008-08-13 2018-10-20 Vertex Pharma Farmaceutska kompozicija n-[2,4-bis(1,1- dimeтileтil)-5-hidroksifenil]- 1,4-dihidro-4-oksohinolin-3-karboksamida i njeno ordiniranje
JP2012504143A (ja) 2008-09-29 2012-02-16 バーテックス ファーマシューティカルズ インコーポレイテッド ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の用量単位
BRPI0919930A2 (pt) 2008-10-23 2016-02-16 Vertex Pharma moduladores de regulador de condutância transmembrana de fibrose cística
NZ592694A (en) 2008-11-06 2013-05-31 Vertex Pharma ATP-Binding Cassette (ABC) transporters as modulators of CFTR activity
UA104876C2 (uk) 2008-11-06 2014-03-25 Вертекс Фармасьютікалз Інкорпорейтед Модулятори atф-зв'язувальних касетних транспортерів
JP5202764B2 (ja) * 2009-06-03 2013-06-05 アルギファルマ エーエス 細菌における多剤耐性の克服に使用されるアルギネートオリゴマー
CA2777245A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
MX2012011655A (es) 2010-04-07 2012-11-23 Vertex Pharma Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo [d][1-3]dioxol-5-il]ciclopropanocarboxamido)-3-metilpiridin-2-il) benzoico.
HRP20211752T1 (hr) 2010-04-07 2022-02-18 Vertex Pharmaceuticals Incorporated Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
WO2011133956A1 (en) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
NZ603043A (en) 2010-04-22 2015-02-27 Vertex Pharma Pharmaceutical compositions comprising cftr modulators and administrations thereof
ES2858351T3 (es) 2010-04-22 2021-09-30 Vertex Pharma Compuesto intermedio para proceso de producción de compuestos de cicloalquilcaraboxamido-indol
AU2011242452A1 (en) 2010-04-22 2012-11-08 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
NZ603386A (en) 2010-05-20 2015-02-27 Vertex Pharma Pharmaceutical compositions and administrations thereof
CN102302477B (zh) * 2011-06-02 2013-08-28 张振海 一种华蟾酥毒基干粉吸入剂及其制备方法、应用
RU2650636C2 (ru) * 2012-05-03 2018-04-16 Янссен Сайенсиз Айрлэнд Юси Составы на основе полиинозиновой-полицитидиловой кислоты (poly(i:с)) для лечения инфекций верхних дыхательных путей
CA2940560A1 (en) 2014-02-28 2015-09-03 Algipharma As Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective cftr ion channel function

Also Published As

Publication number Publication date
CN106659689A (zh) 2017-05-10
KR102582982B1 (ko) 2023-09-25
CN113384538A (zh) 2021-09-14
FI3185853T3 (fi) 2024-02-22
AU2015308381A1 (en) 2017-04-06
CA2959101A1 (en) 2016-03-03
RU2708397C1 (ru) 2019-12-06
JP6707076B2 (ja) 2020-06-10
US20180235879A1 (en) 2018-08-23
EP3185853A1 (en) 2017-07-05
JP2017530952A (ja) 2017-10-19
AU2015308381B2 (en) 2020-10-22
US20210386666A1 (en) 2021-12-16
WO2016030524A1 (en) 2016-03-03
GB201415381D0 (en) 2014-10-15
US11992553B2 (en) 2024-05-28
EP3185853B1 (en) 2024-01-31
CN106659689B (zh) 2021-07-13
KR20170044670A (ko) 2017-04-25
ES2972433T3 (es) 2024-06-12
DK3185853T3 (da) 2024-02-26

Similar Documents

Publication Publication Date Title
BR112017004048A2 (pt) formulações de pó inalável de oligômeros de alginato
MX2022004103A (es) Una formulacion de rapamicina inhalable para tratar afecciones relacionadas con la edad.
BR112015021814A2 (pt) aglomerados respiráveis de partículas carreadoras porosas e fármaco micronizado
BR112017010551A2 (pt) composto, métodos para ativação de guanilato ciclase solúvel, para tratamento de uma ou mais condições selecionadas a partir de uma doença em um paciente e para tratamento de uma doença ou condição, composição farmacêutica, uso de um composto, e, medicamento.
BR112019001141A2 (pt) compostos diaza-heterobicíclicos substituídos e uso dos mesmos
MX2019003397A (es) Metodos para tratar trastornos mitocondriales y metabolicos.
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
MY186229A (en) A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
BR112017006842A2 (pt) formulação de rapamicina inalável para o tratamento de hipertensão pulmonar
MX2016009231A (es) Administracion de tasimelteon en condiciones de ayuno.
MX2017009122A (es) Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol.
ZA202104378B (en) Dry powder inhalation formulation and its use for the therapeutic treatment of lungs
MX369346B (es) Particulas inhalables que comprenden una combinacion de un anticolinergico, un corticosteroide y un beta-adrenergico.
BR112017003731A2 (pt) composições e métodos para prevenir ou tratar doenças, condições ou processos distinguidos por proliferação anormal de fibroblasto e deposição de matriz extracelular
BR112016024488A2 (pt) compostos de ciclo-hexenila, composições que compreendem esses e o uso dos mesmos
PH12015502203A1 (en) Phenyl derivative
BR112017014861A2 (pt) ?combinação e composição farmacêuticas, inalador de pó seco, uso de uma combinação farmacêutica, e, método para tratamento de um distúrbio pulmonar?
BR112017003888A2 (pt) método de fabricação de uma formulação de pó seco, formulação, inalador de pó seco, uso de partículas comoídas por jatos e cocondicionadas, e, kit farmacêutico.
PT3257516T (pt) Composição farmacêutica compreendendo cetraria islandica ach., hialuronato de sódio e uma solução salina para tratamento de doenças do sistema respiratório
PH12017500323A1 (en) P38 map kinase inhibiting indanyl urea compounds
BR112018006279A2 (pt) nova formulação e métodos de tratamento
IN2014MN02133A (pt)
BR112018070521A2 (pt) processo para preparação de formulações sólidas de mesalazina
WO2016016820A3 (en) Anionically modified n-sulfonic polyallylamine derivative, pharmaceutical composition comprising the n-sulfonic polyallylamine derivative as the active substance and use of said derivate for the production of a medicine
AR098868A1 (es) Composición farmacéutica en polvo seco para inhalación

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2737 DE 20/06/2023.